Masterflex SE (ISIN: DE0005492938) has reported preliminary results for the 2025 financial year, showing record earnings and revenue growth within its forecast range. Consolidated revenue rose 4.6% to €102.6 million (previous year: €98.1 million), aligning with the Management Board's forecast of €100 million to €105 million. Operating EBITDA increased 7.4% to a record €19.5 million, while operating EBIT climbed 9.8% to €14.0 million, also a new record. EBIT reached €13.7 million (previous year: €12.5 million), within the €12 million to €15 million forecast.
The company attributed its success to strong performance in the US subgroup and dynamic demand growth in medical technology, which increased its share of consolidated revenue from 18% in 2024 to 21% in 2025. Despite a challenging economic environment, particularly in Germany, demand in industrial sectors and trading declined only moderately. The order backlog remained stable at €19.8 million, matching the previous year's level.
Masterflex also strengthened its financial position, with the equity ratio improving to 73.3% (previous year: 67.7%) and net debt falling to €2.7 million from €9.0 million. The debt ratio (net debt/EBITDA) improved to 0.1 (previous year: 0.5). CEO Dr Andreas Bastin commented, “We met our forecasts, achieved solid revenue growth and slightly increased profitability thanks to continuous efficiency improvements. The development of our medical technology business and the further strengthening of our balance sheet are particularly pleasing.”
These preliminary figures are subject to confirmation by auditors and approval by the Supervisory Board. The 2025 consolidated financial statements and 2026 forecast will be published on 31 March 2026. For more information, view the original release on NewMediaWire.
